RxDoctor Payments Data

Derrick Richardson, MD

Gastroenterology · Fort Smith, ARNPI 1992727150

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 549 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 27.4% of the total.

$8,150in general payments, 2019–2025

Across 549 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Gilead$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$906
  • Pfizer$563
  • Johnson & Johnson$554
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$8,02198%
  • Education$1001%
  • Gifts$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,150 in reported general payments places this provider in the 75th percentile of 108 gastroenterology providers in Arkansas.

See all gastroenterology providers in Arkansas

Medicare billing

Part B allowed, 2024
$178,704
Medicare patients
821
Services billed
1,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase20$88,574
Humira PenAdalimumab12$81,739
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates487$30,986
MovantikNaloxegol Oxalate29$17,606
PentasaMesalamine12$13,080
LinzessLinaclotide15$9,754
SutabSod Sulf/Pot Chloride/Mag Sulf32$5,177
Mesalamine ErMesalamine29$5,049
Pantoprazole Sodium576$4,055
Balsalazide Disodium19$2,083
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl136$1,890
Sucralfate36$1,848
Colestipol Hcl18$1,786
SuprepSodium, Potassium,mag Sulfates15$1,385
Metoclopramide Hcl136$1,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,233$98,32835 claims
Braintree Laboratories, Inc.Sutab$168$5,17732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 108 gastroenterology providers in Arkansas.

Other gastroenterology in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →